Table III.
Prevalence of comorbidities among patients with different persistent periods of atopic dermatitis
| Total |
1 year |
2–5 years |
≥6 years |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (N = 12,780) |
(N = 5039) |
(N = 6609) |
(N = 1078) |
|||||||||
| N | SPR | 95% CI | N | SPR | 95% CI | N | SPR | 95% CI | N | SPR | 95% CI | |
| Autoimmune disorders | ||||||||||||
| All | 203 | 1.59 | (1.57–1.61) | 69 | 1.39 | (1.37–1.41) | 104 | 1.66 | (1.64–1.68) | 30 | 2.21 | (2.19–2.23) |
| Rheumatoid arthritis | 92 | 1.46 | (1.43–1.49) | 35 | 1.44 | (1.41–1.46) | 45 | 1.36 | (1.33–1.39) | 12 | 2.17 | (2.13–2.20) |
| Systemic lupus erythematosus | 39 | 2.43 | (2.36–2.50) | 11 | 1.40 | (1.35–1.46) | 21 | 3.29 | (3.21–3.38) | 7 | 3.44 | (3.36–3.52) |
| Ankylosing spondylitis | 89 | 1.64 | (1.61–1.67) | 28 | 1.38 | (1.35–1.40) | 46 | 1.65 | (1.62–1.68) | 15 | 2.57 | (2.54–2.67) |
| Atopic disorders | ||||||||||||
| All | 5199 | 1.70 | (1.69–1.70) | 1647 | 1.43 | (1.43–1.44) | 2982 | 1.84 | (1.83–1.84) | 570 | 2.16 | (2.16–2.17) |
| Asthma | 2538 | 1.99 | (1.98–2.00) | 742 | 1.60 | (1.59–1.61) | 1502 | 2.17 | (2.16–2.18) | 294 | 2.91 | (2.90–2.93) |
| Allergic rhinitis | 4498 | 1.72 | (1.71–1.73) | 1374 | 1.43 | (1.42–1.43) | 2611 | 1.88 | (1.87–1.88) | 513 | 2.24 | (2.23–2.25) |
| Ocular disorders | ||||||||||||
| All | 4218 | 1.37 | (1.37–1.37) | 1340 | 1.19 | (1.18–1.19) | 2371 | 1.47 | (1.46–1.47) | 507 | 1.67 | (1.67–1.68) |
| Conjunctivitis | 4071 | 1.39 | (1.38–1.39) | 1287 | 1.19 | (1.19–1.20) | 2288 | 1.49 | (1.48–1.49) | 496 | 1.73 | (1.72–1.73) |
| Cataracts | 857 | 1.27 | (1.26–1.27) | 262 | 1.13 | (1.12–1.14) | 495 | 1.36 | (1.36–1.37) | 100 | 1.25 | (1.24–1.26) |
| Glaucoma | 238 | 1.69 | (1.67–1.71) | 75 | 1.46 | (1.44–1.48) | 133 | 1.80 | (1.78–1.82) | 30 | 1.92 | (1.90–1.95) |
| Chronic urticaria | 1751 | 3.14 | (3.12–3.15) | 539 | 2.51 | (2.49–2.52) | 936 | 3.32 | (3.30–3.33) | 276 | 4.82 | (4.80–4.84) |
| Metabolic disorders | ||||||||||||
| All | 1634 | 1.34 | (1.33–1.34) | 578 | 1.28 | (1.28–1.29) | 847 | 1.36 | (1.36–1.37) | 209 | 1.50 | (1.50–1.51) |
| Diabetes mellitus | 942 | 1.46 | (1.45–1.47) | 324 | 1.38 | (1.37–1.39) | 491 | 1.48 | (1.47–1.49) | 127 | 1.71 | (1.70–1.72) |
| Lipid disorders | 1289 | 1.29 | (1.28–1.30) | 464 | 1.24 | (1.23–1.25) | 662 | 1.30 | (1.29–1.31) | 163 | 1.42 | (1.42–1.43) |
| Hypertensive disorders | ||||||||||||
| All | 1821 | 1.16 | (1.16–1.17) | 617 | 1.11 | (1.10–1.11) | 987 | 1.21 | (1.20–1.21) | 217 | 1.19 | (1.19–1.20) |
| Essential hypertension | 1695 | 1.17 | (1.17–1.18) | 571 | 1.11 | (1.10–1.11) | 929 | 1.24 | (1.23–1.25) | 195 | 1.15 | (1.15–1.16) |
| Hypertensive heart disease | 761 | 1.24 | (1.23–1.25) | 248 | 1.15 | (1.15–1.16) | 420 | 1.27 | (1.26–1.28) | 93 | 1.37 | (1.36–1.38) |
| Ischemic heart diseases | ||||||||||||
| All | 774 | 1.24 | (1.23–1.25) | 244 | 1.11 | (1.10–1.12) | 427 | 1.29 | (1.29–1.30) | 103 | 1.44 | (1.44–1.45) |
| Acute myocardial infarction | 123 | 1.33 | (1.31–1.35) | 41 | 1.32 | (1.30–1.35) | 65 | 1.23 | (1.21–1.26) | 17 | 1.45 | (1.43–1.48) |
| Angina pectoris | 246 | 1.28 | (1.26–1.30) | 80 | 1.19 | (1.17–1.20) | 131 | 1.25 | (1.23–1.26) | 35 | 1.75 | (1.73–1.76) |
| Other forms of chronic ischemic heart disease | 612 | 1.25 | (1.24–1.26) | 183 | 1.05 | (1.05–1.06) | 349 | 1.37 | (1.36–1.38) | 80 | 1.42 | (1.41–1.43) |
| Cerebrovascular disorders | ||||||||||||
| All | 354 | 1.17 | (1.16–1.18) | 121 | 1.26 | (1.24–1.27) | 182 | 2.02 | (2.00–2.04) | 36 | 1.82 | (1.80–1.84) |
| Occlusion of cerebral arteries | 286 | 1.09 | (1.07–1.10) | 105 | 1.18 | (1.17–1.19) | 150 | 1.08 | (1.07–1.10) | 31 | 1.03 | (1.01–1.04) |
| Occlusion and stenosis of precerebral arteries | 104 | 1.82 | (1.78–1.85) | 38 | 2.09 | (2.05–2.13) | 53 | 1.73 | (1.70–1.77) | 13 | 1.61 | (1.58–1.65) |
| Psychiatric disorders | ||||||||||||
| All | 1476 | 1.40 | (1.40–1.41) | 623 | 1.31 | (1.30–1.31) | 910 | 1.49 | (1.49–1.50) | 179 | 1.40 | (1.39–1.41) |
| Psychiatric disorders, including episodic mood disorders | 266 | 1.72 | (1.70–1.74) | 101 | 1.51 | (1.50–1.53) | 138 | 1.90 | (1.88–1.92) | 27 | 1.63 | (1.62–1.65) |
| Anxiety, dissociative and somatoform disorders | 1244 | 1.44 | (1.44–1.45) | 471 | 1.37 | (1.36–138) | 642 | 1.52 | (1.51–1.53) | 131 | 1.41 | (1.41–1.42) |
| Nonorganic sleep disorder | 383 | 1.53 | (1.52–1.54) | 139 | 1.35 | (1.34–1.36) | 211 | 1.78 | (1.77–1.79) | 33 | 1.14 | (1.12–1.15) |
| Adjustment reaction | 83 | 1.48 | (1.45–1.51) | 29 | 1.34 | (1.31–1.36) | 46 | 1.61 | (1.58–1.64) | 8 | 1.35 | (1.32–1.37) |
| Depressive disorder | 167 | 1.60 | (1.58–1.63) | 57 | 1.34 | (1.32–1.36) | 90 | 1.80 | (1.77–1.82) | 20 | 1.87 | (1.85–1.90) |
| Attention-deficit/hyperactivity disorder | 272 | 1.11 | (1.09–1.14) | 77 | 0.83 | (0.81–0.85) | 170 | 1.27 | (1.25–1.30) | 25 | 1.49 | (1.46–1.52) |
CI, Confidence interval; SPR, standardized prevalence ratio.